ArticleJournal of cellular and molecular medicine2024

New synergistic combination therapy approaches with HDAC inhibitor quisinostat, cisplatin or PARP inhibitor talazoparib for urothelial carcinoma.

Sarah Meneceur et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.